nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfadiazine—CYP3A4—Thiotepa—urinary bladder cancer	0.12	0.206	CbGbCtD
Sulfadiazine—CYP2E1—Etoposide—urinary bladder cancer	0.108	0.184	CbGbCtD
Sulfadiazine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0964	0.165	CbGbCtD
Sulfadiazine—CYP2C8—Etoposide—urinary bladder cancer	0.0805	0.138	CbGbCtD
Sulfadiazine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0673	0.115	CbGbCtD
Sulfadiazine—CYP2C9—Cisplatin—urinary bladder cancer	0.0571	0.0978	CbGbCtD
Sulfadiazine—CYP3A4—Etoposide—urinary bladder cancer	0.0326	0.0559	CbGbCtD
Sulfadiazine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0223	0.0381	CbGbCtD
Sulfadiazine—Sulfamethoxazole—NAT1—urinary bladder cancer	0.00874	0.513	CrCbGaD
Sulfadiazine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00343	0.0403	CbGpPWpGaD
Sulfadiazine—CYP2E1—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00341	0.0401	CbGpPWpGaD
Sulfadiazine—CYP2C8—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00295	0.0347	CbGpPWpGaD
Sulfadiazine—CYP2E1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00277	0.0325	CbGpPWpGaD
Sulfadiazine—Sulfamethoxazole—NAT2—urinary bladder cancer	0.00275	0.162	CrCbGaD
Sulfadiazine—CYP2C9—urine—urinary bladder cancer	0.00275	0.192	CbGeAlD
Sulfadiazine—CYP2E1—urine—urinary bladder cancer	0.00261	0.182	CbGeAlD
Sulfadiazine—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0024	0.0282	CbGpPWpGaD
Sulfadiazine—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00239	0.0281	CbGpPWpGaD
Sulfadiazine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00229	0.0269	CbGpPWpGaD
Sulfadiazine—Dapsone—NAT2—urinary bladder cancer	0.00215	0.126	CrCbGaD
Sulfadiazine—CYP3A4—urine—urinary bladder cancer	0.0021	0.146	CbGeAlD
Sulfadiazine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00209	0.0246	CbGpPWpGaD
Sulfadiazine—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00195	0.0229	CbGpPWpGaD
Sulfadiazine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00186	0.0219	CbGpPWpGaD
Sulfadiazine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00179	0.021	CbGpPWpGaD
Sulfadiazine—CYP2E1—Folate-Alcohol and Cancer Pathway—MTHFR—urinary bladder cancer	0.00176	0.0207	CbGpPWpGaD
Sulfadiazine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00158	0.0186	CbGpPWpGaD
Sulfadiazine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00147	0.0173	CbGpPWpGaD
Sulfadiazine—Sulfasalazine—PPARG—urinary bladder cancer	0.00139	0.0819	CrCbGaD
Sulfadiazine—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00133	0.0156	CbGpPWpGaD
Sulfadiazine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00133	0.0156	CbGpPWpGaD
Sulfadiazine—CYP2E1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00131	0.0154	CbGpPWpGaD
Sulfadiazine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00128	0.0151	CbGpPWpGaD
Sulfadiazine—Pancreatitis—Cisplatin—urinary bladder cancer	0.00121	0.00404	CcSEcCtD
Sulfadiazine—Blood disorder—Epirubicin—urinary bladder cancer	0.00121	0.00404	CcSEcCtD
Sulfadiazine—Skin discolouration—Methotrexate—urinary bladder cancer	0.00119	0.00399	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.00118	0.00393	CcSEcCtD
Sulfadiazine—Tinnitus—Thiotepa—urinary bladder cancer	0.00117	0.00392	CcSEcCtD
Sulfadiazine—Oliguria—Methotrexate—urinary bladder cancer	0.00117	0.00391	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00117	0.00391	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Gemcitabine—urinary bladder cancer	0.00116	0.00386	CcSEcCtD
Sulfadiazine—Stomatitis—Gemcitabine—urinary bladder cancer	0.00115	0.00384	CcSEcCtD
Sulfadiazine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00115	0.0135	CbGpPWpGaD
Sulfadiazine—Neuropathy peripheral—Fluorouracil—urinary bladder cancer	0.00114	0.0038	CcSEcCtD
Sulfadiazine—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00113	0.0133	CbGpPWpGaD
Sulfadiazine—Vomiting—Mitomycin—urinary bladder cancer	0.00113	0.00378	CcSEcCtD
Sulfadiazine—Stomatitis—Fluorouracil—urinary bladder cancer	0.00113	0.00378	CcSEcCtD
Sulfadiazine—Chills—Thiotepa—urinary bladder cancer	0.00113	0.00377	CcSEcCtD
Sulfadiazine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00113	0.0133	CbGpPWpGaD
Sulfadiazine—Rash—Mitomycin—urinary bladder cancer	0.00112	0.00374	CcSEcCtD
Sulfadiazine—Dermatitis—Mitomycin—urinary bladder cancer	0.00112	0.00374	CcSEcCtD
Sulfadiazine—Blood disorder—Doxorubicin—urinary bladder cancer	0.00112	0.00373	CcSEcCtD
Sulfadiazine—Skin discolouration—Epirubicin—urinary bladder cancer	0.00112	0.00373	CcSEcCtD
Sulfadiazine—Headache—Mitomycin—urinary bladder cancer	0.00111	0.00372	CcSEcCtD
Sulfadiazine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.0011	0.00368	CcSEcCtD
Sulfadiazine—Oliguria—Epirubicin—urinary bladder cancer	0.00109	0.00366	CcSEcCtD
Sulfadiazine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00108	0.00361	CcSEcCtD
Sulfadiazine—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00108	0.0127	CbGpPWpGaD
Sulfadiazine—Neuropathy peripheral—Cisplatin—urinary bladder cancer	0.00108	0.0036	CcSEcCtD
Sulfadiazine—CYP2E1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00108	0.0126	CbGpPWpGaD
Sulfadiazine—Stomatitis—Cisplatin—urinary bladder cancer	0.00107	0.00358	CcSEcCtD
Sulfadiazine—Nausea—Mitomycin—urinary bladder cancer	0.00106	0.00353	CcSEcCtD
Sulfadiazine—Skin discolouration—Doxorubicin—urinary bladder cancer	0.00103	0.00345	CcSEcCtD
Sulfadiazine—Skin exfoliation—Methotrexate—urinary bladder cancer	0.00103	0.00344	CcSEcCtD
Sulfadiazine—Dapsone—MPO—urinary bladder cancer	0.00102	0.0598	CrCbGaD
Sulfadiazine—Oliguria—Doxorubicin—urinary bladder cancer	0.00101	0.00338	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00101	0.00338	CcSEcCtD
Sulfadiazine—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.001	0.00334	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000998	0.00333	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000986	0.0033	CcSEcCtD
Sulfadiazine—Stomatitis—Etoposide—urinary bladder cancer	0.000981	0.00328	CcSEcCtD
Sulfadiazine—Leukopenia—Thiotepa—urinary bladder cancer	0.00098	0.00328	CcSEcCtD
Sulfadiazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000969	0.0114	CbGpPWpGaD
Sulfadiazine—Skin exfoliation—Epirubicin—urinary bladder cancer	0.000963	0.00322	CcSEcCtD
Sulfadiazine—Chills—Gemcitabine—urinary bladder cancer	0.000949	0.00317	CcSEcCtD
Sulfadiazine—Convulsion—Thiotepa—urinary bladder cancer	0.000948	0.00317	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.000947	0.00316	CcSEcCtD
Sulfadiazine—Agranulocytosis—Etoposide—urinary bladder cancer	0.000939	0.00314	CcSEcCtD
Sulfadiazine—CYP2E1—prostate gland—urinary bladder cancer	0.000935	0.0653	CbGeAlD
Sulfadiazine—Sepsis—Methotrexate—urinary bladder cancer	0.000935	0.00313	CcSEcCtD
Sulfadiazine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000933	0.011	CbGpPWpGaD
Sulfadiazine—Arthralgia—Thiotepa—urinary bladder cancer	0.000932	0.00312	CcSEcCtD
Sulfadiazine—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00093	0.0109	CbGpPWpGaD
Sulfadiazine—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000921	0.0108	CbGpPWpGaD
Sulfadiazine—Tinnitus—Cisplatin—urinary bladder cancer	0.000919	0.00307	CcSEcCtD
Sulfadiazine—Polyuria—Methotrexate—urinary bladder cancer	0.000891	0.00298	CcSEcCtD
Sulfadiazine—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.000891	0.00298	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.000876	0.00293	CcSEcCtD
Sulfadiazine—Sepsis—Epirubicin—urinary bladder cancer	0.000875	0.00292	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000875	0.00292	CcSEcCtD
Sulfadiazine—Erythema multiforme—Etoposide—urinary bladder cancer	0.000854	0.00286	CcSEcCtD
Sulfadiazine—Anorexia—Thiotepa—urinary bladder cancer	0.000852	0.00285	CcSEcCtD
Sulfadiazine—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.000829	0.00277	CcSEcCtD
Sulfadiazine—Leukopenia—Gemcitabine—urinary bladder cancer	0.000824	0.00276	CcSEcCtD
Sulfadiazine—Vascular purpura—Epirubicin—urinary bladder cancer	0.000818	0.00274	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000814	0.00272	CcSEcCtD
Sulfadiazine—Chills—Etoposide—urinary bladder cancer	0.000811	0.00271	CcSEcCtD
Sulfadiazine—Leukopenia—Fluorouracil—urinary bladder cancer	0.00081	0.00271	CcSEcCtD
Sulfadiazine—Sepsis—Doxorubicin—urinary bladder cancer	0.00081	0.00271	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.000808	0.0027	CcSEcCtD
Sulfadiazine—CYP2E1—seminal vesicle—urinary bladder cancer	0.000791	0.0552	CbGeAlD
Sulfadiazine—Convulsion—Fluorouracil—urinary bladder cancer	0.000784	0.00262	CcSEcCtD
Sulfadiazine—Arthralgia—Gemcitabine—urinary bladder cancer	0.000784	0.00262	CcSEcCtD
Sulfadiazine—Decreased appetite—Thiotepa—urinary bladder cancer	0.000777	0.0026	CcSEcCtD
Sulfadiazine—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000776	0.00259	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000771	0.00258	CcSEcCtD
Sulfadiazine—Leukopenia—Cisplatin—urinary bladder cancer	0.000768	0.00257	CcSEcCtD
Sulfadiazine—Purpura—Epirubicin—urinary bladder cancer	0.000759	0.00254	CcSEcCtD
Sulfadiazine—CYP2C8—renal system—urinary bladder cancer	0.000757	0.0529	CbGeAlD
Sulfadiazine—Vascular purpura—Doxorubicin—urinary bladder cancer	0.000757	0.00253	CcSEcCtD
Sulfadiazine—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000756	0.00889	CbGpPWpGaD
Sulfadiazine—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000756	0.00253	CcSEcCtD
Sulfadiazine—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000754	0.00886	CbGpPWpGaD
Sulfadiazine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000752	0.00251	CcSEcCtD
Sulfadiazine—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00075	0.00251	CcSEcCtD
Sulfadiazine—Convulsion—Cisplatin—urinary bladder cancer	0.000744	0.00249	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000739	0.00247	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000736	0.00246	CcSEcCtD
Sulfadiazine—Ataxia—Methotrexate—urinary bladder cancer	0.000735	0.00246	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000732	0.0086	CbGpPWpGaD
Sulfadiazine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000731	0.00244	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000724	0.00242	CcSEcCtD
Sulfadiazine—CYP2E1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000722	0.00848	CbGpPWpGaD
Sulfadiazine—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.000718	0.0024	CcSEcCtD
Sulfadiazine—Anorexia—Gemcitabine—urinary bladder cancer	0.000716	0.00239	CcSEcCtD
Sulfadiazine—Urticaria—Thiotepa—urinary bladder cancer	0.00071	0.00237	CcSEcCtD
Sulfadiazine—Vertigo—Etoposide—urinary bladder cancer	0.000707	0.00236	CcSEcCtD
Sulfadiazine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000706	0.00236	CcSEcCtD
Sulfadiazine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000706	0.00236	CcSEcCtD
Sulfadiazine—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000706	0.00829	CbGpPWpGaD
Sulfadiazine—Anorexia—Fluorouracil—urinary bladder cancer	0.000704	0.00235	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000704	0.00235	CcSEcCtD
Sulfadiazine—Leukopenia—Etoposide—urinary bladder cancer	0.000704	0.00235	CcSEcCtD
Sulfadiazine—Purpura—Doxorubicin—urinary bladder cancer	0.000703	0.00235	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000701	0.00234	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.0007	0.00234	CcSEcCtD
Sulfadiazine—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000694	0.00232	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—NAT1—urinary bladder cancer	0.000694	0.00815	CbGpPWpGaD
Sulfadiazine—CYP2E1—Biological oxidations—GSTO2—urinary bladder cancer	0.000694	0.00815	CbGpPWpGaD
Sulfadiazine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000691	0.00812	CbGpPWpGaD
Sulfadiazine—Ataxia—Epirubicin—urinary bladder cancer	0.000688	0.0023	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000686	0.00229	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000685	0.00229	CcSEcCtD
Sulfadiazine—CYP2E1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000684	0.00804	CbGpPWpGaD
Sulfadiazine—Convulsion—Etoposide—urinary bladder cancer	0.000681	0.00228	CcSEcCtD
Sulfadiazine—Insomnia—Gemcitabine—urinary bladder cancer	0.00068	0.00227	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000673	0.00225	CcSEcCtD
Sulfadiazine—Insomnia—Fluorouracil—urinary bladder cancer	0.000668	0.00223	CcSEcCtD
Sulfadiazine—Anorexia—Cisplatin—urinary bladder cancer	0.000668	0.00223	CcSEcCtD
Sulfadiazine—Pancreatitis—Methotrexate—urinary bladder cancer	0.000663	0.00222	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000659	0.0022	CcSEcCtD
Sulfadiazine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000658	0.0022	CcSEcCtD
Sulfadiazine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000653	0.00218	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000649	0.00217	CcSEcCtD
Sulfadiazine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000642	0.00215	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000642	0.00215	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000638	0.00213	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000638	0.00213	CcSEcCtD
Sulfadiazine—CYP2E1—renal system—urinary bladder cancer	0.000638	0.0445	CbGeAlD
Sulfadiazine—Ataxia—Doxorubicin—urinary bladder cancer	0.000637	0.00213	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000634	0.00746	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.000632	0.00743	CbGpPWpGaD
Sulfadiazine—Pruritus—Thiotepa—urinary bladder cancer	0.000632	0.00211	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000628	0.0021	CcSEcCtD
Sulfadiazine—CYP2E1—urethra—urinary bladder cancer	0.000626	0.0437	CbGeAlD
Sulfadiazine—CYP2E1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000626	0.00735	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000624	0.00733	CbGpPWpGaD
Sulfadiazine—Pancreatitis—Epirubicin—urinary bladder cancer	0.00062	0.00207	CcSEcCtD
Sulfadiazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000615	0.00723	CbGpPWpGaD
Sulfadiazine—Anorexia—Etoposide—urinary bladder cancer	0.000612	0.00204	CcSEcCtD
Sulfadiazine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000611	0.00204	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00061	0.00204	CcSEcCtD
Sulfadiazine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000609	0.00204	CcSEcCtD
Sulfadiazine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000607	0.00714	CbGpPWpGaD
Sulfadiazine—CYP2C8—female reproductive system—urinary bladder cancer	0.000607	0.0423	CbGeAlD
Sulfadiazine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000605	0.00202	CcSEcCtD
Sulfadiazine—Depression—Methotrexate—urinary bladder cancer	0.000601	0.00201	CcSEcCtD
Sulfadiazine—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.0006	0.00705	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.0006	0.00705	CbGpPWpGaD
Sulfadiazine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000598	0.002	CcSEcCtD
Sulfadiazine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000594	0.00199	CcSEcCtD
Sulfadiazine—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000591	0.00695	CbGpPWpGaD
Sulfadiazine—Sulfasalazine—PTGS2—urinary bladder cancer	0.000588	0.0346	CrCbGaD
Sulfadiazine—Stomatitis—Methotrexate—urinary bladder cancer	0.000588	0.00196	CcSEcCtD
Sulfadiazine—Urticaria—Fluorouracil—urinary bladder cancer	0.000587	0.00196	CcSEcCtD
Sulfadiazine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000584	0.00195	CcSEcCtD
Sulfadiazine—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000574	0.00675	CbGpPWpGaD
Sulfadiazine—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000574	0.00192	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000571	0.00671	CbGpPWpGaD
Sulfadiazine—Vomiting—Thiotepa—urinary bladder cancer	0.000568	0.0019	CcSEcCtD
Sulfadiazine—CYP2E1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000563	0.00662	CbGpPWpGaD
Sulfadiazine—Rash—Thiotepa—urinary bladder cancer	0.000563	0.00188	CcSEcCtD
Sulfadiazine—Dermatitis—Thiotepa—urinary bladder cancer	0.000563	0.00188	CcSEcCtD
Sulfadiazine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000562	0.00188	CcSEcCtD
Sulfadiazine—Headache—Thiotepa—urinary bladder cancer	0.00056	0.00187	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000559	0.00187	CcSEcCtD
Sulfadiazine—Decreased appetite—Etoposide—urinary bladder cancer	0.000558	0.00186	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000554	0.00185	CcSEcCtD
Sulfadiazine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000554	0.00185	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000553	0.00185	CcSEcCtD
Sulfadiazine—Stomatitis—Epirubicin—urinary bladder cancer	0.00055	0.00184	CcSEcCtD
Sulfadiazine—CYP2C8—vagina—urinary bladder cancer	0.000549	0.0383	CbGeAlD
Sulfadiazine—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000548	0.00644	CbGpPWpGaD
Sulfadiazine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000544	0.00182	CcSEcCtD
Sulfadiazine—Hepatitis—Methotrexate—urinary bladder cancer	0.000541	0.00181	CcSEcCtD
Sulfadiazine—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000541	0.00636	CbGpPWpGaD
Sulfadiazine—CYP2C9—female reproductive system—urinary bladder cancer	0.000539	0.0376	CbGeAlD
Sulfadiazine—Pruritus—Gemcitabine—urinary bladder cancer	0.000532	0.00178	CcSEcCtD
Sulfadiazine—Nausea—Thiotepa—urinary bladder cancer	0.000531	0.00177	CcSEcCtD
Sulfadiazine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00053	0.00623	CbGpPWpGaD
Sulfadiazine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000526	0.00176	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000525	0.00175	CcSEcCtD
Sulfadiazine—Pruritus—Fluorouracil—urinary bladder cancer	0.000523	0.00175	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000517	0.00173	CcSEcCtD
Sulfadiazine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000516	0.00173	CcSEcCtD
Sulfadiazine—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000515	0.00605	CbGpPWpGaD
Sulfadiazine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000514	0.00172	CcSEcCtD
Sulfadiazine—CYP3A4—renal system—urinary bladder cancer	0.000513	0.0358	CbGeAlD
Sulfadiazine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000512	0.00171	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000512	0.00171	CcSEcCtD
Sulfadiazine—CYP2E1—female reproductive system—urinary bladder cancer	0.000511	0.0356	CbGeAlD
Sulfadiazine—Urticaria—Etoposide—urinary bladder cancer	0.00051	0.0017	CcSEcCtD
Sulfadiazine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000509	0.0017	CcSEcCtD
Sulfadiazine—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000508	0.00597	CbGpPWpGaD
Sulfadiazine—Body temperature increased—Etoposide—urinary bladder cancer	0.000507	0.0017	CcSEcCtD
Sulfadiazine—Abdominal pain—Etoposide—urinary bladder cancer	0.000507	0.0017	CcSEcCtD
Sulfadiazine—Hepatitis—Epirubicin—urinary bladder cancer	0.000506	0.00169	CcSEcCtD
Sulfadiazine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000506	0.00169	CcSEcCtD
Sulfadiazine—Tinnitus—Methotrexate—urinary bladder cancer	0.000504	0.00169	CcSEcCtD
Sulfadiazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000499	0.00586	CbGpPWpGaD
Sulfadiazine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000497	0.00584	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.000494	0.0058	CbGpPWpGaD
Sulfadiazine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000492	0.00578	CbGpPWpGaD
Sulfadiazine—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000488	0.00573	CbGpPWpGaD
Sulfadiazine—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000488	0.00573	CbGpPWpGaD
Sulfadiazine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000487	0.00163	CcSEcCtD
Sulfadiazine—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000487	0.00572	CbGpPWpGaD
Sulfadiazine—Chills—Methotrexate—urinary bladder cancer	0.000485	0.00162	CcSEcCtD
Sulfadiazine—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000481	0.00566	CbGpPWpGaD
Sulfadiazine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000479	0.0016	CcSEcCtD
Sulfadiazine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000479	0.0016	CcSEcCtD
Sulfadiazine—Vomiting—Gemcitabine—urinary bladder cancer	0.000478	0.0016	CcSEcCtD
Sulfadiazine—Rash—Gemcitabine—urinary bladder cancer	0.000474	0.00158	CcSEcCtD
Sulfadiazine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000473	0.00158	CcSEcCtD
Sulfadiazine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000473	0.00158	CcSEcCtD
Sulfadiazine—Tinnitus—Epirubicin—urinary bladder cancer	0.000472	0.00158	CcSEcCtD
Sulfadiazine—Headache—Gemcitabine—urinary bladder cancer	0.000471	0.00157	CcSEcCtD
Sulfadiazine—Vomiting—Fluorouracil—urinary bladder cancer	0.00047	0.00157	CcSEcCtD
Sulfadiazine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000469	0.00157	CcSEcCtD
Sulfadiazine—Rash—Fluorouracil—urinary bladder cancer	0.000466	0.00156	CcSEcCtD
Sulfadiazine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000465	0.00156	CcSEcCtD
Sulfadiazine—Headache—Fluorouracil—urinary bladder cancer	0.000463	0.00155	CcSEcCtD
Sulfadiazine—Chills—Epirubicin—urinary bladder cancer	0.000454	0.00152	CcSEcCtD
Sulfadiazine—Pruritus—Etoposide—urinary bladder cancer	0.000454	0.00152	CcSEcCtD
Sulfadiazine—Nausea—Gemcitabine—urinary bladder cancer	0.000446	0.00149	CcSEcCtD
Sulfadiazine—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000446	0.00525	CbGpPWpGaD
Sulfadiazine—Vomiting—Cisplatin—urinary bladder cancer	0.000445	0.00149	CcSEcCtD
Sulfadiazine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000443	0.00148	CcSEcCtD
Sulfadiazine—Rash—Cisplatin—urinary bladder cancer	0.000442	0.00148	CcSEcCtD
Sulfadiazine—Dermatitis—Cisplatin—urinary bladder cancer	0.000441	0.00148	CcSEcCtD
Sulfadiazine—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00044	0.00517	CbGpPWpGaD
Sulfadiazine—Diarrhoea—Etoposide—urinary bladder cancer	0.000439	0.00147	CcSEcCtD
Sulfadiazine—Nausea—Fluorouracil—urinary bladder cancer	0.000439	0.00147	CcSEcCtD
Sulfadiazine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000437	0.00146	CcSEcCtD
Sulfadiazine—Vertigo—Methotrexate—urinary bladder cancer	0.000423	0.00141	CcSEcCtD
Sulfadiazine—Leukopenia—Methotrexate—urinary bladder cancer	0.000422	0.00141	CcSEcCtD
Sulfadiazine—Chills—Doxorubicin—urinary bladder cancer	0.00042	0.00141	CcSEcCtD
Sulfadiazine—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000417	0.00491	CbGpPWpGaD
Sulfadiazine—Nausea—Cisplatin—urinary bladder cancer	0.000416	0.00139	CcSEcCtD
Sulfadiazine—CYP3A4—female reproductive system—urinary bladder cancer	0.000411	0.0287	CbGeAlD
Sulfadiazine—Convulsion—Methotrexate—urinary bladder cancer	0.000408	0.00136	CcSEcCtD
Sulfadiazine—Vomiting—Etoposide—urinary bladder cancer	0.000408	0.00136	CcSEcCtD
Sulfadiazine—Rash—Etoposide—urinary bladder cancer	0.000405	0.00135	CcSEcCtD
Sulfadiazine—Dermatitis—Etoposide—urinary bladder cancer	0.000404	0.00135	CcSEcCtD
Sulfadiazine—Headache—Etoposide—urinary bladder cancer	0.000402	0.00134	CcSEcCtD
Sulfadiazine—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000402	0.00472	CbGpPWpGaD
Sulfadiazine—Arthralgia—Methotrexate—urinary bladder cancer	0.000401	0.00134	CcSEcCtD
Sulfadiazine—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000396	0.00466	CbGpPWpGaD
Sulfadiazine—Vertigo—Epirubicin—urinary bladder cancer	0.000396	0.00132	CcSEcCtD
Sulfadiazine—Leukopenia—Epirubicin—urinary bladder cancer	0.000395	0.00132	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000384	0.00128	CcSEcCtD
Sulfadiazine—Convulsion—Epirubicin—urinary bladder cancer	0.000382	0.00128	CcSEcCtD
Sulfadiazine—Dapsone—PTGS2—urinary bladder cancer	0.000381	0.0224	CrCbGaD
Sulfadiazine—Nausea—Etoposide—urinary bladder cancer	0.000381	0.00127	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—NAT2—urinary bladder cancer	0.00038	0.00447	CbGpPWpGaD
Sulfadiazine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000376	0.00126	CcSEcCtD
Sulfadiazine—Arthralgia—Epirubicin—urinary bladder cancer	0.000375	0.00125	CcSEcCtD
Sulfadiazine—CYP2E1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000375	0.00441	CbGpPWpGaD
Sulfadiazine—Vertigo—Doxorubicin—urinary bladder cancer	0.000366	0.00122	CcSEcCtD
Sulfadiazine—Anorexia—Methotrexate—urinary bladder cancer	0.000366	0.00122	CcSEcCtD
Sulfadiazine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000365	0.00122	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00036	0.0012	CcSEcCtD
Sulfadiazine—Convulsion—Doxorubicin—urinary bladder cancer	0.000353	0.00118	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000352	0.00118	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00035	0.00117	CcSEcCtD
Sulfadiazine—Insomnia—Methotrexate—urinary bladder cancer	0.000348	0.00116	CcSEcCtD
Sulfadiazine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000347	0.00116	CcSEcCtD
Sulfadiazine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000346	0.00407	CbGpPWpGaD
Sulfadiazine—Anorexia—Epirubicin—urinary bladder cancer	0.000343	0.00115	CcSEcCtD
Sulfadiazine—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00034	0.00399	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000339	0.00399	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000335	0.00393	CbGpPWpGaD
Sulfadiazine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000334	0.00112	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000333	0.00111	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000332	0.00111	CcSEcCtD
Sulfadiazine—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000329	0.00386	CbGpPWpGaD
Sulfadiazine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000328	0.0011	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000326	0.00109	CcSEcCtD
Sulfadiazine—Insomnia—Epirubicin—urinary bladder cancer	0.000325	0.00109	CcSEcCtD
Sulfadiazine—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000324	0.00381	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000322	0.00378	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000322	0.00378	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000317	0.00373	CbGpPWpGaD
Sulfadiazine—Anorexia—Doxorubicin—urinary bladder cancer	0.000317	0.00106	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000314	0.00105	CcSEcCtD
Sulfadiazine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000313	0.00105	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000311	0.00104	CcSEcCtD
Sulfadiazine—Urticaria—Methotrexate—urinary bladder cancer	0.000305	0.00102	CcSEcCtD
Sulfadiazine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000304	0.00102	CcSEcCtD
Sulfadiazine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000304	0.00102	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—HPGDS—urinary bladder cancer	0.000304	0.00357	CbGpPWpGaD
Sulfadiazine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000303	0.00101	CcSEcCtD
Sulfadiazine—Insomnia—Doxorubicin—urinary bladder cancer	0.000301	0.00101	CcSEcCtD
Sulfadiazine—CYP2E1—Biological oxidations—GSTT1—urinary bladder cancer	0.000295	0.00346	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000294	0.00346	CbGpPWpGaD
Sulfadiazine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000294	0.000983	CcSEcCtD
Sulfadiazine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00029	0.00341	CbGpPWpGaD
Sulfadiazine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000289	0.000967	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000287	0.000961	CcSEcCtD
Sulfadiazine—Urticaria—Epirubicin—urinary bladder cancer	0.000286	0.000955	CcSEcCtD
Sulfadiazine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000284	0.000951	CcSEcCtD
Sulfadiazine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000284	0.000951	CcSEcCtD
Sulfadiazine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000283	0.000947	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000272	0.00091	CcSEcCtD
Sulfadiazine—Pruritus—Methotrexate—urinary bladder cancer	0.000272	0.000909	CcSEcCtD
Sulfadiazine—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000267	0.00314	CbGpPWpGaD
Sulfadiazine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000265	0.000886	CcSEcCtD
Sulfadiazine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000265	0.00311	CbGpPWpGaD
Sulfadiazine—Urticaria—Doxorubicin—urinary bladder cancer	0.000264	0.000884	CcSEcCtD
Sulfadiazine—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000264	0.0031	CbGpPWpGaD
Sulfadiazine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000263	0.00088	CcSEcCtD
Sulfadiazine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000263	0.00088	CcSEcCtD
Sulfadiazine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000263	0.000879	CcSEcCtD
Sulfadiazine—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000263	0.00309	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000261	0.00307	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000255	0.00299	CbGpPWpGaD
Sulfadiazine—Pruritus—Epirubicin—urinary bladder cancer	0.000255	0.000851	CcSEcCtD
Sulfadiazine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000246	0.000823	CcSEcCtD
Sulfadiazine—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000246	0.00289	CbGpPWpGaD
Sulfadiazine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000245	0.00082	CcSEcCtD
Sulfadiazine—Vomiting—Methotrexate—urinary bladder cancer	0.000244	0.000817	CcSEcCtD
Sulfadiazine—Rash—Methotrexate—urinary bladder cancer	0.000242	0.00081	CcSEcCtD
Sulfadiazine—Dermatitis—Methotrexate—urinary bladder cancer	0.000242	0.000809	CcSEcCtD
Sulfadiazine—Headache—Methotrexate—urinary bladder cancer	0.000241	0.000805	CcSEcCtD
Sulfadiazine—Pruritus—Doxorubicin—urinary bladder cancer	0.000236	0.000787	CcSEcCtD
Sulfadiazine—Vomiting—Epirubicin—urinary bladder cancer	0.000229	0.000765	CcSEcCtD
Sulfadiazine—Nausea—Methotrexate—urinary bladder cancer	0.000228	0.000763	CcSEcCtD
Sulfadiazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000228	0.00268	CbGpPWpGaD
Sulfadiazine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000228	0.000761	CcSEcCtD
Sulfadiazine—Rash—Epirubicin—urinary bladder cancer	0.000227	0.000758	CcSEcCtD
Sulfadiazine—Dermatitis—Epirubicin—urinary bladder cancer	0.000227	0.000758	CcSEcCtD
Sulfadiazine—Headache—Epirubicin—urinary bladder cancer	0.000225	0.000753	CcSEcCtD
Sulfadiazine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000214	0.00251	CbGpPWpGaD
Sulfadiazine—Nausea—Epirubicin—urinary bladder cancer	0.000214	0.000714	CcSEcCtD
Sulfadiazine—Vomiting—Doxorubicin—urinary bladder cancer	0.000212	0.000707	CcSEcCtD
Sulfadiazine—Rash—Doxorubicin—urinary bladder cancer	0.00021	0.000702	CcSEcCtD
Sulfadiazine—Dermatitis—Doxorubicin—urinary bladder cancer	0.00021	0.000701	CcSEcCtD
Sulfadiazine—Headache—Doxorubicin—urinary bladder cancer	0.000209	0.000697	CcSEcCtD
Sulfadiazine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000207	0.00244	CbGpPWpGaD
Sulfadiazine—CYP2E1—Biological oxidations—GSTP1—urinary bladder cancer	0.000204	0.0024	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000201	0.00237	CbGpPWpGaD
Sulfadiazine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.0002	0.00235	CbGpPWpGaD
Sulfadiazine—Nausea—Doxorubicin—urinary bladder cancer	0.000198	0.000661	CcSEcCtD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00019	0.00223	CbGpPWpGaD
Sulfadiazine—CYP2E1—Biological oxidations—GSTM1—urinary bladder cancer	0.000188	0.00221	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000185	0.00218	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000177	0.00208	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000176	0.00207	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000174	0.00205	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000174	0.00204	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000162	0.00191	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00016	0.00188	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000154	0.00181	CbGpPWpGaD
Sulfadiazine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000144	0.00169	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000142	0.00167	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000141	0.00166	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000137	0.00161	CbGpPWpGaD
Sulfadiazine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000132	0.00155	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00013	0.00153	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	0.000125	0.00147	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	0.000119	0.00139	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—NAT1—urinary bladder cancer	0.000119	0.00139	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	0.000108	0.00128	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000108	0.00127	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	0.000103	0.00121	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—NAT1—urinary bladder cancer	0.000103	0.00121	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000101	0.00119	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	9.77e-05	0.00115	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	9.48e-05	0.00111	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	9.38e-05	0.0011	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.35e-05	0.0011	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	9.23e-05	0.00108	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	8.99e-05	0.00106	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	8.8e-05	0.00103	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	8.71e-05	0.00102	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.59e-05	0.00101	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	8.44e-05	0.000992	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	8.35e-05	0.000981	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	8.35e-05	0.000981	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.21e-05	0.000965	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	7.97e-05	0.000937	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	7.77e-05	0.000913	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	7.63e-05	0.000897	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—TYMP—urinary bladder cancer	7.19e-05	0.000845	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	6.87e-05	0.000808	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—NAT2—urinary bladder cancer	6.5e-05	0.000764	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.49e-05	0.000763	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	6.32e-05	0.000743	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.23e-05	0.000732	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—TYMP—urinary bladder cancer	6.21e-05	0.00073	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.97e-05	0.000701	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.81e-05	0.000682	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—NAT2—urinary bladder cancer	5.62e-05	0.00066	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—RRM2—urinary bladder cancer	5.61e-05	0.000659	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.5e-05	0.000647	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.5e-05	0.000647	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—ENO2—urinary bladder cancer	5.2e-05	0.000611	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	5.2e-05	0.000611	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.07e-05	0.000596	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	5.06e-05	0.000594	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	5.04e-05	0.000592	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.03e-05	0.000592	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.86e-05	0.000571	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.85e-05	0.00057	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.57e-05	0.000537	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.53e-05	0.000533	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	4.49e-05	0.000528	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	4.49e-05	0.000528	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.47e-05	0.000525	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	4.36e-05	0.000512	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.29e-05	0.000504	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.28e-05	0.000503	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—NQO1—urinary bladder cancer	4.19e-05	0.000492	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.17e-05	0.00049	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.95e-05	0.000464	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.66e-05	0.00043	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.66e-05	0.00043	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.63e-05	0.000427	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.62e-05	0.000425	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.55e-05	0.000417	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.51e-05	0.000413	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	3.49e-05	0.000411	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.49e-05	0.00041	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.33e-05	0.000392	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—TYMS—urinary bladder cancer	3.25e-05	0.000382	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	3.21e-05	0.000377	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	3.21e-05	0.000377	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GPX1—urinary bladder cancer	3.07e-05	0.000361	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.06e-05	0.00036	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	3.02e-05	0.000355	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	3.02e-05	0.000355	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.02e-05	0.000354	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.95e-05	0.000346	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.92e-05	0.000343	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.86e-05	0.000336	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	2.84e-05	0.000333	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.81e-05	0.00033	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.77e-05	0.000326	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.77e-05	0.000326	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.66e-05	0.000312	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.61e-05	0.000307	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.6e-05	0.000306	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.49e-05	0.000293	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.46e-05	0.000289	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.45e-05	0.000288	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.41e-05	0.000283	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.41e-05	0.000283	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.38e-05	0.000279	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.34e-05	0.000275	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	2.3e-05	0.00027	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.28e-05	0.000269	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.26e-05	0.000265	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.26e-05	0.000265	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	2.21e-05	0.00026	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.16e-05	0.000254	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.12e-05	0.00025	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2e-05	0.000235	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.99e-05	0.000234	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.94e-05	0.000228	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.91e-05	0.000225	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.81e-05	0.000213	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.62e-05	0.00019	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.62e-05	0.00019	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.58e-05	0.000185	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.56e-05	0.000184	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.55e-05	0.000183	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.51e-05	0.000177	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.51e-05	0.000177	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.49e-05	0.000175	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.49e-05	0.000175	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.43e-05	0.000168	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.4e-05	0.000165	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.36e-05	0.00016	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.32e-05	0.000155	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.3e-05	0.000153	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.27e-05	0.00015	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.11e-05	0.00013	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.07e-05	0.000125	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.06e-05	0.000124	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.03e-05	0.000121	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.4e-06	9.87e-05	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.32e-06	8.61e-05	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.98e-06	8.21e-05	CbGpPWpGaD
